Pakistan earns $10m from phase 3 trials of CanSino
July 12, 2021
ISLAMABAD: The National Institute of Health (NIH) Executive Director Major General Aamer Ikram has revealed that Pakistan earned a whopping $10m from conducting phase 3 trials of the Chinese vaccine CanSino.
The NIH has played an important role in the efforts to check dissemination of coronavirus under the General who was speaking at a function where he disclosed that many countries wanted to hold their phase 3 trials in Pakistan. “These experiments can bring millions of dollars into Pakistan,” he said.
Major General Aamer Ikram said that Pakistan had also started co-manufacturing the single-dose Adenovirus-vectored Covid-19 vaccine with CanSino Bio at the NIH Islamabad, and claimed that within a year, they were hopeful of earning around $30 million through the joint manufacturing of the vaccine in the country. “And this successful venture has opened doors of numerous more such opportunities for Pakistan and
July 11, 2021
Pakistan has earned $10 million by conducting first-ever Phase-III clinical trials for the single-dose Chinese Covid-19 vaccine CanSino Bio at five leading public and private health facilities in the country, and now the National Institute of Health (NIH) is going to earn 30 million dollars within a year by co-manufacturing the same vaccine after technology transfer from China, officials said on Saturday.
“Phase-III clinical trials of the CanSino Biologics single-dose Covid-19 were the first-ever such trials conducted in Pakistan and we earned $10 million by conducting these trials at five centres in Karachi, Lahore and Islamabad. Now we are being approached by companies from the UK, Korea and Japan, as well as from China for conducting Phase-III clinical trials of several more vaccines, which can earn us huge revenue and foreign exchange,” said Major General Aamer Ikram, executive director of the National Institute of Health Islamabad, at a health conference in
WHO support strengthens testing capacity for COVID-19 in Pakistan
Format
27 June 2021 – Dr Palitha Mahipala, WHO Representative in Pakistan, handed over a PCR machine and biosafety cabinet for Mianwali district to Major General Aamer Ikram, Executive Director, National Institute of Health in Islamabad, during an event at the WHO country office in Islamabad. WHO has so far delivered 32 PCR machines and other equipment to improve testing capacity for COVID-19 testing in Pakistan. The equipment aims to enhance laboratory testing capacity for COVID-19. WHO in Pakistan is collaborating with the National Institute of Health to strengthen testing capacity and genomic surveillance for SARS-CoV2 variants.
Saudi Arabia is expected to approve Chinese Covid vaccines for pilgrims soon: Sindh Chief Minister--China Economic Net en.ce.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from en.ce.cn Daily Mail and Mail on Sunday newspapers.